Pharmaceutical manufacturers should be able to share clinical and economic information about unapproved drugs with certain payer representatives at least 12 to 18 months prior to FDA approval, according to new recommendations from an Academy of Managed Care Pharmacy-led group.
A safe harbor for "preapproval information exchange" would allow payers to factor in the potential cost and clinical impact of...






